Combinatory approaches prevent preterm birth profoundly exacerbated by gene-environment interactions

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 4063-4075

  Cha, Jeeyeon ^a   Bartos, Amanda ^a   Egashira, Mahiro ^b   Haraguchi, Hirofumi ^b   Saito Fujita, Tomoko ^b   Leishman, Emma ^c   Bradshaw, Heather ^c   Dey, Sudhansu K ^a   Hirota, Yasushi ^a,b,d  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c INDIANA UNIVERSITY   (United States)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; MAMMALIAN TARGET OF RAPAMYCIN; PROGESTERONE; RAPAMYCIN; 3 ALPHA-BETA, 20 BETA-HYDROXYSTEROID DEHYDROGENASE; 3ALPHA(OR 20BETA) HYDROXYSTEROID DEHYDROGENASE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GLYCOPROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PRLPI PROTEIN, MOUSE; PROLACTIN RECEPTOR; PROTEIN P53; PTGS2 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; DECIDUA; DISEASE EXACERBATION; FEMALE; FETAL WELL BEING; GENE DELETION; GENETIC PREDISPOSITION; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK PREGNANCY; HUMAN; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MATERNAL WELFARE; OVARY; PREMATURE LABOR; PRIORITY JOURNAL; SENESCENCE; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; PREGNANCY; PREMATURE BIRTH; TRANSGENIC MOUSE;

20-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DECIDUA; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION; GENE-ENVIRONMENT INTERACTION; GLYCOPROTEINS; LIPOPOLYSACCHARIDES; MICE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; OVARY; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PYRAZOLES; RECEPTORS, PROLACTIN; SIGNAL TRANSDUCTION; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883544312     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70098     Document Type: Article

References (80)

1. WHO. Born Too Soon: The Global Action Report on Preterm Birth. Geneva, Switzerland: World Health Organization; 2012.
2. Behrman R, Butler AS, eds. Preterm Birth: Causes, Consequences, and Prevention. Washington DC, USA: The National Academies Press; 2007.
3. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75-84.
4. Blencowe H, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162- 2172.
5. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008;371(9608):261-269.
6. Liu L, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379(9832):2151-2161.
7. Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med. 2008;359(3):262-273. (Pubitemid 352008441)
8. Muglia LJ, Katz M. The enigma of spontaneous preterm birth. N Engl J Med. 2010;362(6):529-535.
9. Elovitz MA, Mrinalini C. Animal models of preterm birth. Trends Endocrinol Metab. 2004;15(10):479-487. (Pubitemid 39488151)
10. Dudley DJ, Branch DW, Edwin SS, Mitchell MD. Induction of preterm birth in mice by RU486. Biol Reprod. 1996;55(5):992-995. (Pubitemid 26346531)
11. Challis JRG, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev. 2000;21(5):514-550.
12. Cha J, Sun X, Dey SK. Mechanisms of implantation: strategies for successful pregnancy. Nat Med. 2012;18(12):1754-1767.
13. Hirota Y, Daikoku T, Tranguch S, Xie H, Bradshaw HB, Dey SK. Uterine-specific p53 deficiency confers premature uterine senescence and promotes preterm birth in mice. J Clin Invest. 2010;120(3):803-815.
14. Hirota Y, Cha J, Yoshie M, Daikoku T, Dey SK. Heightened uterine mammalian target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice. Proc Natl Acad Sci U S A. 2011; 108(44):18073-18078.
15. Renthal NE, Chen CC, Williams KC, Gerard RD, Prange-Kiel J, Mendelson CR. miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor. Proc Natl Acad Sci U S A. 2010;107(48):20828-20833.
16. Simhan HN, Caritis SN. Prevention of preterm delivery. N Engl J Med. 2007;357(5):477-487.
17. Ratajczak CK, Muglia LJ. Insights into parturition biology from genetically altered mice. Pediatr Res. 2008;64(6):581-589.
18. Barkai U, Prigent-Tessier A, Tessier C, Gibori GB, Gibori G. Involvement of SOCS-1, the suppressor of cytokine signaling, in the prevention of prolactin-responsive gene expression in decidual cells. Mol Endocrinol. 2000;14(4):554-563. (Pubitemid 32260524)
19. Erlebacher A, Zhang D, Parlow AF, Glimcher LH. Ovarian insufficiency and early pregnancy loss induced by activation of the innate immune system. J Clin Invest. 2004;114(1):39-48. (Pubitemid 39071642)
20. Herz Z, Khan I, Jayatilak PG, Gibori G. Evidence for the secretion of decidual luteotropin: a prolactinlike hormone produced by rat decidual cells. Endocrinology. 1986;118(6):2203-2209. (Pubitemid 16058384)
21. Bao L, et al. Decidual prolactin silences the expression of genes detrimental to pregnancy. Endocrinology. 2007;148(5):2326-2334. (Pubitemid 46997084)
22. Jayatilak PG, Glaser LA, Basuray R, Kelly PA, Gibori G. Identification and partial characterization of a prolactin-like hormone produced by rat decidual tissue. Proc Natl Acad Sci U S A. 1985;82(1):217-221. (Pubitemid 15168246)
23. Gibori G, Rothchild I, Pepe GJ, Morishige WK, Lam P. Luteotrophic action of decidual tissue in the rat. Endocrinology. 1974;95(4):1113-1118.
24. Burnum KE, et al. Uterine deletion of Trp53 compromises antioxidant responses in the mouse decidua. Endocrinology. 2012;153(9):4568-4579.
25. Alam SM, Konno T, Sahgal N, Lu L, Soares MJ. Decidual cells produce a heparin-binding prolactin family cytokine with putative intrauterine regulatory actions. J Biol Chem. 2008;283(27):18957-18968.
26. Hiraoka Y, et al. PLP-I: a novel prolactin-like gene in rodents. Biochim Biophys Acta. 1999;1447(2-3):291-297. (Pubitemid 29495004)
27. Toft DJ, Linzer DI. Prolactin (PRL)-like protein J, a novel member of the PRL/growth hormone family, is exclusively expressed in maternal decidua. Endocrinology. 1999;140(11):5095-5101.
28. Ishibashi K, Imai M. Identification of four new members of the rat prolactin/growth hormone gene family. Biochem Biophys Res Commun. 1999; 262(3):575-578. (Pubitemid 29443698)
29. Binart N, et al. Rescue of preimplantatory egg development and embryo implantation in prolactin receptor-deficient mice after progesterone administration. Endocrinology. 2000;141(7):2691-2697. (Pubitemid 32269091)
30. Reese J, et al. Implantation and decidualization defects in prolactin receptor (PRLR)-deficient mice are mediated by ovarian but not uterine PRLR. Endocrinology. 2000;141(5):1872-1881. (Pubitemid 32274417)
31. Mah LJ, El-Osta A, Karagiannis TC. GammaH2AX as a molecular marker of aging and disease. Epigenetics. 2010;5(2):129-136.
32. Mackenzie AP, Schatz F, Krikun G, Funai EF, Kadner S, Lockwood CJ. Mechanisms of abruption-induced premature rupture of the fetal membranes: thrombin enhanced decidual matrix metalloproteinase-3 (stromelysin-1) expression. Am J Obstet Gynecol. 2004;191(6):1996-2001. (Pubitemid 39601504)
33. Siiteri PK, Febres F, Clemens LE, Chang RJ, Gondos B, Stites D. Progesterone and maintenance of pregnancy: is progesterone nature's immunosuppressant? Ann N Y Acad Sci. 1977;286:384-397.
34. Matheu A, et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature. 2007;448(7151):375-379. (Pubitemid 47080339)
35. Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ. Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A. 2007;104(42):16633-16638. (Pubitemid 350211068)
36. Rodier F, Campisi J, Bhaumik D. Two faces of p53: aging and tumor suppression. Nucleic Acids Res. 2007; 35(22):7475-7484.
37. Donehower LA. Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb Perspect Biol. 2009;1(6):a001081.
38. Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A. 2010; 107(21):9660-9664.
39. Telleria CM, Ou J, Sugino N, Ferguson S, Gibori G. The expression of interleukin-6 in the pregnant rat corpus luteum and its regulation by progesterone and glucocorticoid. Endocrinology. 1998; 139(8):3597-3605. (Pubitemid 28512319)
40. Gibori G, Kalison B, Basuray R, Rao MC, Hunzicker- Dunn M. Endocrine role of the decidual tissue: decidual luteotropin regulation of luteal adenylyl cyclase activity, luteinizing hormone receptors, and steroidogenesis. Endocrinology. 1984;115(3):1157-1163. (Pubitemid 14074489)
41. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug Saf. 1997;16(4):267-278. (Pubitemid 27186936)
42. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000; 356(9225):194-202. (Pubitemid 30446974)
43. Rapamune (sirolimus) maintenance regimen. Summary for presentation to the Subcomittee of the Antiviral Drugs Advisory Committee on Immunosuppressive Drugs. 24 January 2002. http:/www.fda.gov/ohrms/dockets/ac/02/briefing/3832b1- 01-Wyreth-Ayerst.pdf. Accessed August 12, 2013.
44. Dey SK, et al. Molecular cues to implantation. Endocr Rev. 2004;25(3):341-373. (Pubitemid 38780665)
45. Wang H, Dey SK. Roadmap to embryo implantation: clues from mouse models. Nat Rev Genet. 2006; 7(3):185-199. (Pubitemid 43361530)
46. American College of Obstetrics and Gynecologist Committee Opinion. Use of progesterone to reduce preterm birth. Int J Gynaecol Obstet. 2004;84(1):93-94.
47. Meis PJ, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379-2385. (Pubitemid 36682816)
48. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening G. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357(5):462-469. (Pubitemid 47204875)
49. Johnson JW, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med. 1975;293(14):675-680.
50. Romero R. Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. Ultrasound Obstet Gynecol. 2007; 30(5):675-686. (Pubitemid 47612688)
51. Romero R, Yeo L, Miranda J, Hassan SS, Conde- Agudelo A, Chaiworapongsa T. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med. 2013;41(1):27-44.
52. Kang HJ, et al. Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A. 2009;106(24):9761-9766.
53. Patounakis G, Treff N, Tao X, Lonczak A, Scott RT, Frattarelli JL. The p53 codon 72 single nucleotide polymorphism lacks a significant effect on implantation rate in fresh in vitro fertilization cycles: an analysis of 1,056 patients. Fertil Steril. 2009; 92(4):1290-1296.
54. de Keizer PL, Laberge RM, Campisi J. p53: proaging or pro-longevity? Aging (Albany NY). 2010; 2(7):377-379.
55. Tranguch S, et al. Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc Natl Acad Sci U S A. 2005; 102(40):14326-14331. (Pubitemid 41429697)
56. Tranguch S, Wang H, Daikoku T, Xie H, Smith DF, Dey SK. FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. J Clin Invest. 2007; 117(7):1824-1834. (Pubitemid 47036316)
57. Hirota Y, et al. Uterine FK506-binding protein 52 (FKBP52)-peroxiredoxin- 6 (PRDX6) signaling protects pregnancy from overt oxidative stress. Proc Natl Acad Sci U S A. 2010;107(35):15577-15582.
58. Krizhanovsky V, et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657-667.
59. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol. 2004;6(2):168-170. (Pubitemid 38425717)
60. Villee DB. Development of endocrine function in the human placenta and fetus (second of two parts). N Engl J Med. 1969;281(10):533-541.
61. Lachelin GC, McGarrigle HH, Seed PT, Briley A, Shennan AH, Poston L. Low saliva progesterone concentrations are associated with spontaneous early preterm labour (before 34 weeks of gestation) in women at increased risk of preterm delivery. BJOG. 2009;116(11):1515-1519.
62. Klebanoff MA, et al. Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo. Am J Obstet Gynecol. 2008;199(5):506.e1-506.e7.
63. Williams KC, Renthal NE, Condon JC, Gerard RD, Mendelson CR. MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm labor. Proc Natl Acad Sci U S A. 2012;109(19):7529-7534.
64. Nakajima T, et al. Expression of 20alpha-hydroxysteroid dehydrogenase mRNA in human endometrium and decidua. Endocr J. 2003;50(1):105-111. (Pubitemid 36305854)
65. Pieber D, Allport VC, Hills F, Johnson M, Bennett PR. Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol Hum Reprod. 2001;7(9):875-879. (Pubitemid 32842756)
66. Pieber D, Allport VC, Bennett PR. Progesterone receptor isoform A inhibits isoform B-mediated transactivation in human amnion. Eur J Pharmacol. 2001;427(1):7-11. (Pubitemid 32831059)
67. Mesiano S, Wang Y, Norwitz ER. Progesterone receptors in the human pregnancy uterus: do they hold the key to birth timing? Reprod Sci. 2011;18(1):6-19.
68. Brown AG, Leite RS, Strauss JF. Mechanisms underlying "functional" progesterone withdrawal at parturition. Ann N Y Acad Sci. 2004;1034:36-49. (Pubitemid 40362348)
69. van der Burg B, van der Saag PT. Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. Mol Hum Reprod. 1996;2(6):433-438.
70. Madsen G, Zakar T, Ku CY, Sanborn BM, Smith R, Mesiano S. Prostaglandins differentially modulate progesterone receptor-A and -B expression in human myometrial cells: evidence for prostaglandin-induced functional progesterone withdrawal. J Clin Endocrinol Metab. 2004;89(2):1010-1013. (Pubitemid 38269925)
71. Goldman S, Weiss A, Almalah I, Shalev E. Progesterone receptor expression in human decidua and fetal membranes before and after contractions: possible mechanism for functional progesterone withdrawal. Mol Hum Reprod. 2005;11(4):269-277. (Pubitemid 40662812)
72. Merlino A, et al. Nuclear progesterone receptor expression in the human fetal membranes and decidua at term before and after labor. Reprod Sci. 2009;16(4):357-363.
73. Lockwood CJ, Stocco C, Murk W, Kayisli UA, Funai EF, Schatz F. Human labor is associated with reduced decidual cell expression of progesterone, but not glucocorticoid, receptors. J Clin Endocrinol Metab. 2010;95(5):2271-2275.
74. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130(2):223-233. (Pubitemid 47081143)
75. Cnattingius S, Forman MR, Berendes HW, Isotalo L. Delayed childbearing and risk of adverse perinatal outcome. A population-based study. JAMA. 1992;268(7):886-890.
76. Roberts CL, Algert CS, March LM. Delayed child-bearing - are there any risks? Med J Aust. 1994; 160(9):539-544. (Pubitemid 24127593)
77. Carolan M. The graying of the obstetric population: implications for the older mother. J Obstet Gynecol Neonatal Nurs. 2003;32(1):19-27.
78. Nelson SM, Lawlor DA. Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144,018 treatment cycles. PLoS Med. 2011;8(1):e1000386.
79. Krieg SA, Henne MB, Westphal LM. Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in vitro fertilization pregnancies. Fertil Steril. 2008;90(1):65-70. (Pubitemid 351885200)
80. Hirata T, et al. Evidence for the presence of toll-like receptor 4 system in the human endometrium. J Clin Endocrinol Metab. 2005;90(1):548-556. (Pubitemid 40116707)